Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zervimesine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPARC
  • Sponsors Cognition Therapeutics

Most Recent Events

  • 06 Mar 2024 According to a Cognition Therapeutics media release, presenting results of proteomic and correlation analyses in posters at the AD/PD 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal).
  • 04 Jan 2024 According to a Cognition Therapeutics media release, manuscript of the complete SPARC results which has been accepted for publication in the journal, Alzheimer's Research & Therapy.
  • 23 May 2023 According to a Cognition Therapeutics media release, the company has released its fifth "Conversations" video podcast, a review and interactive discussion of Cognition's CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference. The company has presents findings from an unbiased proteomic analysis of combined datasets from completed Phase 1b SPARC study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top